Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 34Prostatic Neoplasms, Castration-Resistant 3Metastatic Castration-resistant Prostate Cancer 2Metastatic Castration-Resistant Prostate Cancer 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Prostate Cancer Metastatic Disease 1Prostate Adenocarcinoma 1Newly Diagnosed Oligometastatic Prostate Cancer 1Neoadjuvant Therapy 1Metastatic Hormone-sensitive Prostate Cancer 1Melanoma 1Disease 1Castration-resistant Prostate Cancer 1Castrate Sensitive Prostate Cancer 1Carcinoma, Small Cell 1Carcinoma, Non-Small-Cell Lung 1Anus Neoplasms 1

Interventions

apalutamide 1abiraterone 1Radiosurgery 1Leuprolide 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Newly Diagnosed Oligometastatic Prostate Cancer × abiraterone × Clear all
NCT03298087 2025-08-01

Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer

VA Office of Research and Development

Phase 2 Completed
28 enrolled 10 charts
Genitourinary

Newly Diagnosed Oligometastatic Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡